A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting 180 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.

Timeline

Start: 2024-12-13
Primary completion: 2027-07-31
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SKB500	Unknown	—	Intravenous

A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications